Literature DB >> 8340450

Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection.

D M Bakes1, N D Turner, B H Gordon, M P Hiley, B Walther, C Lucas.   

Abstract

An extraction method has been developed using benzene sulphonyl cation-exchange sample preparation cartridges and reversed-phase high-performance liquid chromatography with ultraviolet detection for the measurement of S9788, a drug to reverse resistance to anticancer agents, in plasma and serum. This includes a toxicokinetic assay which has a mean precision and accuracy of 11.7% and 7.9%, respectively, over the range 10-1000 ng ml-1 and a quantification limit of 10 ng ml-1 and a more sensitive pharmacokinetic procedure with a mean precision and accuracy of 5.0% and 7.9%, respectively, over the range 1-500 ng ml-1 and a quantification limit of 1 ng ml-1. The specificity of the procedure has been demonstrated by mass and ultraviolet spectrometry, and linearity, precision, accuracy, recovery and sensitivity have been established. The assays have been successfully applied to toxicokinetic and pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340450     DOI: 10.1016/0378-4347(93)80297-h

Source DB:  PubMed          Journal:  J Chromatogr


  2 in total

1.  In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.

Authors:  J Soudon; M Berlion; C Lucas; P Haddad; J P Bizzari; F Calvo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Authors:  C J Punt; E E Voest; E Tueni; A T Van Oosterom; A Backx; P H De Mulder; B Hecquet; C Lucas; B Gerard; H Bleiberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.